CytRx reports positive top-line data from aldoxorubicin STS trial

CytRx (CYTR) is out with top-line results from a Phase 2b study of aldoxorubicin in first-line metastatic, locally advanced or unresectable STSs.

Summary (intent-to-treat analysis): Median PFS for aldoxorubicin, 8.4 months; median PFS for doxorubicin, 4.7 months.

Summary (blinded central lab review): Median PFS for aldoxorubicin, 5.7 months; median PFS for doxorubicin, 2.8 months.

OR rate: 25.4% for aldoxorubicin, 5.4% for doxorubicin.

"These results are extraordinary for a single agent treating these chemotherapy-resistant tumors," the study's principal investigator says. (PR)

CYTR +32% premarket.

From other sites
Comments (2)
  • 487371
    , contributor
    Comments (13) | Send Message
    remarkable what effect on share price results from a barely significant clinical effect for any cancer therapy! Does anyone remember DNDN? SRPT is another one with insignificant data (but it took a long time for the FDA to figure that one out.
    11 Dec 2013, 09:33 AM Reply Like
  • Biomaster
    , contributor
    Comments (215) | Send Message
    STRONG clinical effect was results of this trial-
    So what are you talking about?
    Standard of care is very poor in this patient population-
    ANY improvement is significant.
    11 Dec 2013, 10:08 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs